Pre-market Hot Trades in US Stocks
System1 is up 13.67% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 30, System1 reported a year-on-year revenue decline of 31.29%, raising market concerns about its business model. Despite the company's focus on consumer verticals such as shopping, travel, and search, the revenue drop has made investors cautious, leading to a 14.46% decline in pre-market trading. Source: Benzinga
</li>
<li>
On March 30, technical analysis showed that System1's stock price is 22.9% above the 20-day simple moving average but 24.1% below the 100-day simple moving average. This technical signal typically indicates a short-term rebound, but the medium-term trend remains weak. Source: Benzinga
</li>
<li>
On March 30, market sentiment signals indicated a sell, with a current market capitalization of £34.51 million. Although the company provides data-driven insights and tools to help brands and agencies optimize advertising effectiveness, the market remains cautious about its future performance. Source: TipRanks The market is cautious about the advertising industry's outlook.
</li>
</ol>
Iterum Therap is down 11.79% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 31, the FDA requested Iterum Therapeutics to provide additional data to support its supplemental new drug application for ORLYNVAH. The FDA suggested the company hold a Type C meeting to determine trial design and endpoints, a requirement that may lead to additional R&amp;D costs and time delays, impacting the stock price.
</li>
<li>
On March 30, analysts expect Iterum Therapeutics to show revenue growth in its quarterly report to be released on April 1, but with a loss of 14 cents per share. Although the average rating for the stock is &#34;Buy,&#34; market concerns about its financial performance may lead to stock price volatility.
</li>
<li>
On March 28, Iterum Therapeutics initiated liquidation proceedings and experienced leadership changes. This news may raise market concerns about the company's future operational capabilities, leading to a stock price decline. The biotechnology sector has been volatile recently, and policy changes should be monitored.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Hitek Global Inc. is up 122.25% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 27, Hitek Global Inc. announced the sale of 100 million Class A shares to certain institutional investors at a price of $0.03 per share, with the transaction expected to be completed on March 30. This news attracted market attention, leading to a significant pre-market stock price increase. Source: MT Newswires
</li>
<li>
On March 27, Hitek Global Inc. announced a $3 million registered direct offering pricing, demonstrating the company's commitment to expanding its business, further driving the stock price up. Source: Hitek Global Inc
On March 27, Hitek Global Inc. signed a securities purchase agreement with specific entities, indicating the company's commitment to expanding its business in the technology sector and enhancing market confidence. Source: Hitek Global Inc.
</li>
</ol>
Megan pre-market rose 47.13%, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Oxbridge Re pre-market rose 28.96%. Based on recent news,
<ol>
<li>
On March 30, Oxbridge Re Holdings Ltd. released a strong performance report for the fiscal year 2025-26. Despite losses from Hurricane Milton, its tokenized reinsurance products exceeded return targets and expanded the platform through major blockchain partners. The company expects to launch new products in 2026 and reduce disaster risks, which boosted market confidence and drove the stock price up.
</li>
<li>
On March 30, Oxbridge Re Holdings Ltd.'s expense ratio rose to 144.2%, mainly due to increased professional, marketing, tokenization, and legal costs. Despite the rise in expenses, the company's management emphasized its ongoing momentum in the on-chain reinsurance platform and set return targets of 20% and 42% for the next cycle of tokenized products, further enhancing investor confidence.
</li>
<li>
On March 30, Oxbridge Re Holdings Ltd.'s Q4 2025 financial report showed that despite losses from Hurricane Milton and increased tokenization costs, the company achieved revenue growth and a rebound in profitability. The SurancePlus tokenized contracts performed better than expected, and strong liquidity supported the company's expansion into blockchain and AI infrastructure opportunities. This series of positive factors drove the stock price up. The reinsurance industry performed well overall, with increased applications of blockchain technology
</li>
</ol>

ITRM

ITRMF

System1 pre-market up 13.67%; Iterum Therap pre-market down 11.79%; Hitek Global Inc. pre-market up 122.25%; Megan pre-market up 47.13%; Oxbridge Re pre-market up 28.96%

Pre-market hot trades in US stocks: System1 up 13.67% in pre-market; Iterum Therap down 11.79% in pre-market